BRILINTA 90MG TABLET contains Ticagrelor which belongs to the group of medicines called Antiplatelets. It is used in combination with acetylsalicylic acid (a medicine that prevents blood clot) for adults who had heart attack (blockage of blood flow to the heart muscle characterized by tightness or pain in the chest, neck, back or arms, abnormal heartbeat, and anxiety), unstable angina (chest pain that is caused by inadequate blood supply to heart with the symptom of crushing type of pain in chest with mild physical activity). It also reduces the chances of having another heart attack and stroke from other diseases related to heart or blood vessels. Stroke is defined as the damage to the brain from interruption in its blood supply characterized by paralysis, numbness or weakness in the arm, face, and leg, trouble in speaking or understanding others.
BRILINTA 90MG TABLET is not recommended for use in patients having severe liver problem, bleeding currently, stroke because of bleeding. BRILINTA 90MG TABLET should be used in caution with patient having heart disease, lung problems.
If you are pregnant or breast-feeding, consult your doctor for advice before taking BRILINTA 90MG TABLET.
BRILINTA 90MG TABLET is not recommended for use in children and adolescents up to the age of 18 years.
The most common side effects of taking BRILINTA 90MG TABLET includes bleeding, bruising, headache, dizziness. Consult your doctor if the symptom worsens.
BRILINTA 90MG TABLET is used in combination with acetylsalicylic acid (a medicine that prevents blood clot) for adults who have:
BRILINTA 90MG TABLET reduces the clotting of blood and increases the blood flow to vital oragns by preventing the clumping of platelets (small blood cells that stops bleeding from cut or damaged blood vessels).
Take BRILINTA 90MG TABLET as advised by your physician. Swallow this medicine, do not crush, or chew the medicine. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and disease condition.
Stop taking BRILINTA 90MG TABLET and contact your doctor immediately if you experience any of the following side effects:
Drink lots of fluids, such as water or fruit juice to keep yourself hydrated. Do not consume any medicine on your own without consulting your doctor.
When you feel dizzy, lie, or sit down immediately. if you're experiencing a severe episode of vertigo, lie in a dark and quite place with eyes closed. Vehicle driving should be avoided if you experience frequent dizziness without warning. Talk to your doctor if the symptom worsens.
Apply hot or cold-water bag on your head. Try taking rest in a quiet and dark room. Massage with mild pressure on scalp or head.
Take this medicine with, or just after meals. Stick to simple meals. Avoid eating oil rich or spicy foods, sugary snacks, and drinks. Avoid drinking too much liquid along with your meals. Talk to your doctor if your symptom is not improving.
BRILINTA 90MG TABLET is not recommended for use in pregnant women or women planning for pregnancy. Women should use appropriate contraceptive measures to avoid pregnancy while taking this medicine. Consult your doctor before taking BRILINTA 90MG TABLET.
BRILINTA 90MG TABLET should be used during breast-feeding only if clearly considered necessary. Discuss with your doctor before taking BRILINTA 90MG TABLET.
Do not drive or operate any machines as it may can cause side effects such as confusion and dizziness. Talk to your doctor before taking BRILINTA 90MG TABLET.
Consumption of alcohol is not recommended during treatment with BRILINTA 90MG TABLET.
BRILINTA 90MG TABLET should be used with caution in patients having any liver disease or any other disease that affected the liver previously. BRILINTA 90MG TABLET is not recommended for use in patients with severe liver disease. Consult your doctor before taking BRILINTA 90MG TABLET.
BRILINTA 90MG TABLET is not recommended for use if you are allergic to Ticagrelor.
BRILINTA 90MG TABLET should be used in caution with patients having asthma, breathing difficulties or other lung problems. Consult your doctor before taking BRILINTA 90MG TABLET.
BRILINTA 90MG TABLET should be taken with caution in patients having low heart rate (having pacemaker). Before taking BRILINTA 90MG TABLET consult with your doctor.
BRILINTA 90MG TABLET is not recommended for use in children and adolescents (under 18 years of age). Consult your physician before taking BRILINTA 90MG TABLET.
BRILINTA 90MG TABLET is used with caution in patients above 65 years of age. Consult your doctor before taking BRILINTA 90MG TABLET.
BRILINTA 90MG TABLET is not recommended for use if you:
Before taking BRILINTA 90MG TABLET, inform your doctor if you have:
A. Drug - Drug interactions:
Before taking BRILINTA 90MG TABLET, inform your doctor if you are taking any of the following medicine:
Overdosage:
If you or anyone else accidentally take too much of BRILINTA 90MG TABLET, consult your doctor immediately or visit the nearby hospital. You may be at a risk of increased risk of bleeding.
Drug | : | Ticagrelor |
Pharmacological Category | : | Anticoagulant |
Therapeutic Indication | : | Prevention of blood clot |
Dosage Forms | : | Tablet |
A: BRILINTA 90MG TABLET is a blood thinning medication used to reduce the risk of blood clot formation and its associated cardiovascular risks such as heart attack or stroke.
A: BRILINTA 90MG TABLET is safe at doses prescribed by the physician. It should be used under careful medical supervision, as it could increase the risk of bleeding even from minor cuts, scrapes or injuries. It is strictly contraindicated in patients with bleeding conditions and should be reported to hospital, in case of unexpected accidents, injuries or trauma.
A: Yes. BRILINTA 90MG TABLET is effective in blood thinning, where it reduces the risk of coronary heart disease and its associated manifestations.
A: BRILINTA 90MG TABLET is an antiplatelet medicine, which prevents the platelets them from sticking together and forming blood clots. At normal conditions, platelets help to arrest bleeding from cuts and injuries by forming blood clots. However, patients suffering from heart attack, stroke, pulmonary embolism, have improper regulation of platelets in the body which results in abnormal blood clot formation within the blood vessels, leading to circulatory complications.
A: Ticagrelor is commonly prescribed after a heart attack or in cases of acute coronary syndrome to reduce the risk of further cardiovascular events.
A: BRILINTA 90MG TABLET is usually taken orally, with or without food. The prescribed dosage and frequency depend on the individual's medical condition and the healthcare provider's recommendation.
A: The most common side effects of BRILINTA 90MG TABLET are excessive bleeding or bruising (even from minor cuts or wounds), shortness of breath, headache, high blood uric acid levels, dizziness or spinning sensation, joint pain and swelling, and nausea. Consult your doctor if these side effects trouble you.
A: BRILINTA 90MG TABLET is typically prescribed with aspirin to see better results.
A: The duration of therapy with BRILINTA 90MG TABLET varies based on the individual's medical history and the reason for prescription. Some individuals may take it for a short period, while others may require longer-term therapy.
A: BRILINTA 90MG TABLET is not recommended for use during pregnancy, as it could harm the growing baby and increase the risk of bleeding after childbirth. Women of childbearing potential should use a suitable contraceptive agent as a precaution while taking this medicine.
A: Ticagrelor can interact with certain medications, such as blood thinners, antifungal drugs, and some antidepressants. It's crucial to inform the healthcare provider about all medications being taken to avoid potential interactions.
A: If a dose is missed, it's generally recommended to take the missed dose as soon as remembered. However, if it's almost time for the next scheduled dose, it's advisable to skip the missed dose and continue with the regular dosing schedule.
A: Abruptly stopping Ticagrelor without consulting a healthcare provider can increase the risk of cardiovascular events. Any changes to the treatment plan should be discussed with a healthcare professional.
A: Ticagrelor has unique characteristics, including reversible binding to its target receptor and a faster onset of action compared to some other antiplatelet medications.
A: Allergic reactions to Ticagrelor are rare but can occur. Seek medical attention immediately if signs of an allergic reaction, such as rash, itching, or swelling, are observed.
A: Healthcare providers may monitor bleeding parameters, liver function, and other relevant factors during Ticagrelor treatment.
A: It's generally advisable to limit alcohol consumption while taking Ticagrelor, as alcohol can increase the risk of bleeding. However, specific recommendations should be discussed with a healthcare provider.
1. KD.Tripathi. Anticoagulants. Essentials of medical pharmacology. Eighth edition. 2019. Page – 663-667.
2. RaeAnne Fuller and Benjamin Chavez. Ticagrelor (Brilinta), an Antiplatelet Drug for Acute Coronary Syndrome. NIH National Library of Medicine, National center for biotechnology information. PubMed Central October 2012. [Accessed 14th May 2022]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474441/
3. Michal J Kubisa, Mateusz P Jezewski, Aleksandra Gasecka, Jolanta M Siller-Matula, and Marek Postula. Ticagrelor – toward more efficient platelet inhibition and beyond. NIH National Library of Medicine, National center for biotechnology information. PubMed Central. January 2018. [Accessed 14th May 2022]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775739/
4. AstraZeneca AB. Electronic Medicines Compendium (EMC). [Revised in February 2022]. [Accessed 14h May 2022]. https://www.medicines.org.uk/emc/files/pil.5767.pdf
5. AstraZeneca AB. Electronic Medicines Compendium (EMC). [Revised in February 2022]. [Accessed 14h May 2022]. https://www.medicines.org.uk/emc/files/pil.7606.pdf
6. AstraZeneca AB. U.S. Food & Drug Administration [Revised in September 2016] [Accessed 14h May 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022433s020lbl.pdf
Written By Srilekha. R, B.Pharm
Last updated on 23 Mar 2024 | 05:58 PM(IST)
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.